Lawmakers push Mylan on EpiPen price hikes
In letters to Mylan N.V. (NASDAQ:MYL) CEO Heather Bresch, U.S. Sens. Chuck Grassley (R-Iowa) and Richard Blumenthal (D-Conn.) expressed concern that recent increases in EpiPen's price could limit patients' access to the epinephrine auto-injector to treat severe acute allergic reactions. The lawmakers requested information about access programs, pricing and advertising cost transparency, and changes Mylan has made in the product since acquiring it in 2007.
On Saturday, Sen. Amy Klobuchar (D-Minn.) called on the Senate Judiciary Committee to hold a hearing to investigate EpiPen's price and alleged Mylan is "exploiting a monopoly market advantage" due to reduced competition. On Monday, Klobuchar also asked the U.S. Federal Trade Commission to investigate EpiPen's price increase. ...